Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/08/2007US20070259027 Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
11/08/2007US20070259026 Vasodialating dressing for use with intravenous catheters
11/08/2007US20070259025 Absorbent antiviral structure
11/08/2007US20070259022 Composition Comprising Statin
11/08/2007US20070259021 Compositions, Methods, and Kits for Treating Dry Eye
11/08/2007US20070259019 Implant depots to deliver growth factors to treat osteoporotic bone
11/08/2007US20070259014 Compositions for and Methods for Treating Hiv
11/08/2007US20070259013 Pharmaceutical compositions comprising silica microspheres
11/08/2007US20070259009 Aqueous Pharmaceutical Preparation Comprising Roflumilast
11/08/2007US20070259008 Polymalic Acid-Based Multi-Functional Drug Delivery System
11/08/2007US20070258996 Synergistic combination of three or more of sequestering agents, carbohydrates, terpenes or terpenoids, amines, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides or macrolide polyenes; antiobiotic resistance
11/08/2007US20070258994 Immunomodulatory formulations and methods for use thereof
11/08/2007US20070258988 Identification and Characterization of Multiple Splice Variants of the Mu Opioid Receptor Gene
11/08/2007US20070258986 Targeted Delivery System for Bioactive Agents
11/08/2007US20070258985 Human mini-antibody cytotoxic for tumor cells which express the ERB-B2 receptor
11/08/2007US20070258984 Anti-neoplastic composition of 5-FU, leucovorin, irinotecan, oxaliplatin, capecitabine, paclitaxel or doxetaxel; breast cancer, colorectal cancer, rectal cancer, non-small cell lung cancer, non-Hodgkins lymphoma (NHL), renal cell cancer, prostate cancer, liver cancer
11/08/2007US20070258977 Inhibiting OX-2 (also called CD200) gene expression to treat a tumor that is associated with increased CD200 expression; leukemia; phage display screening for antigens; monoclonal antibodies; fusion proteins; use of OX-2 preventing graft rejection, autoimmune disease, and in inducing tumor cell growth
11/08/2007US20070258974 Diagnostics and Therapeutics for Diseases Associated with Puromycin Sensitive Aminopeptidase Npepps (Npepps)
11/08/2007US20070258973 Diagnostics and Therapeutics for Diseases Associated with Tripeptidyl-Peptidase 2(Tpp2)
11/08/2007US20070258972 Combination of a Histone Deacetylase Inhibitor with a Death Receptor Ligand
11/08/2007US20070258970 Methods for Inhibiting Hiv and Other Viral Infections by Modulating Ceramide Metabolism
11/08/2007US20070258969 Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers
11/08/2007US20070258964 Preparing selenium-enriched biomass having Se-methionine content of at least 11.39 ng/mgd.w. by culturing microorganisms selected from Lactobacillus reuteri DSM16143, Lactobacillus ferintoshensis DSM16144 and Lactobacillus buchneri/parabuchneri DSM16341 in culture medium comprising selenium salt
11/08/2007US20070258961 Cholesterol efflux and uses thereof
11/08/2007US20070258951 Methods of treating cardiac disorders
11/08/2007US20070258947 Depeptidized Inhibitors of Hepatitis C Virus NS3 Protease
11/08/2007US20070258944 Multiple cytokine protein complexes
11/08/2007US20070258942 C-Nitroso compounds and use thereof
11/08/2007US20070258941 Methods and compositions for remediation of disc herniation by modifying structure
11/08/2007US20070258939 Drug Delivery from Embolic Agents
11/08/2007US20070258938 Compositions comprising biomembrane sealing agent for treatment of pain or inflammation, and methods of use
11/08/2007US20070258929 4-(Pyrazol-4-ylimino)-2,5-cyclohexadienylidene quaternary ammonium salts; oxidation color dyes, pyrazole dyes, and hair dyes; intense blue; colorfastness, washfastness, storage stability, water solubility
11/08/2007US20070258920 Process for obtaining polyphenol extracts from cocoa beans, the resulting extracts and uses thereof
11/08/2007US20070258912 Use of Fluorescent Whitening Agents as Antimicrobials
11/08/2007US20070258906 Methods and devices for detection and therapy of atheromatous plaque
11/08/2007US20070258892 Composition, Comprising L-Serine, L-Isoleucine, Folic Acid and Trace Elements, for Treating Psoriasis
11/08/2007US20070258890 Anthracycline Derivatives
11/08/2007US20070256685 Aerosol Formulations Comprising Formoterol Fumarate Dihydrate
11/08/2007DE60021370C5 Piperazinderivate verwendbar als ccr5 antagonisten Piperazine derivatives useful as antagonists ccr5
11/08/2007DE202006020095U1 Dosierform enthaltend Oxycodon und Naloxon Dosage form comprising oxycodone and naloxone
11/08/2007DE112005003183T5 Diazen-verbrückte Kronenether-Lithium-Verbindung und Verfahren zu ihrer Verwendung Diazene-bridged crown ether-lithium compound and methods for their use
11/08/2007DE102006012251A1 Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln Substituted 4-amino-quinazoline derivatives and to their use for the preparation of medicaments
11/08/2007CA2823767A1 Abnormal cannabidiols as agents for lowering intraocular pressure
11/08/2007CA2823724A1 Abnormal cannabidiols as agents for lowering intraocular pressure
11/08/2007CA2685356A1 Reducing risk of type 2 diabetes (t2d)
11/08/2007CA2684999A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
11/08/2007CA2669708A1 Benzamide glucokinase activators
11/08/2007CA2661819A1 Fixed combination dosage forms for the treatment of migraine
11/08/2007CA2656990A1 Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
11/08/2007CA2651072A1 Substituted 2-amino-fused heterocyclic compounds
11/08/2007CA2651031A1 Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
11/08/2007CA2651002A1 Use of escitalopram for improving cognition
11/08/2007CA2650914A1 Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
11/08/2007CA2650786A1 Liquid drug formulation
11/08/2007CA2650716A1 Hydroxybutyrate and poly-hydroxybutyrate as components of animal feed or feed additives
11/08/2007CA2650711A1 Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
11/08/2007CA2650704A1 Salts of pyridazine compounds
11/08/2007CA2650686A1 Method for stabilization of reduced coenzyme q10
11/08/2007CA2650683A1 Amine derivative having npy y5 receptor antagonist activity
11/08/2007CA2650668A1 Method for the synthesis of triazole-containing oligonucleotide deratives
11/08/2007CA2650631A1 Crystalline forms of a dimethylphenyl compound
11/08/2007CA2650627A1 Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
11/08/2007CA2650625A1 Formulations containing pyridazine compounds for treating neuroinflammatory diseases
11/08/2007CA2650597A1 Method and composition for treating and preventing tumor metastasis in vivo
11/08/2007CA2650577A1 Use of 12-imidazolyl-1-dodecanol or its pharmaceutically acceptable salts for producing a pharmaceutical preparation
11/08/2007CA2650572A1 Novel aminopyridine derivatives having aurora a selective inhibitory action
11/08/2007CA2650567A1 Use of cbx cannabinoid receptor modulators as potassium channel modulators
11/08/2007CA2650566A1 Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
11/08/2007CA2650530A1 Dialkylphenyl compounds having .beta.2 adrenergic receptor agonist and muscarinic receptor antagonist activity
11/08/2007CA2650480A1 Type 1, 4-naphtoquinone compounds, compositions comprising them and use of these compounds as anti-cancer agents
11/08/2007CA2650473A1 Protein crosslinkers, crosslinking methods and applications thereof
11/08/2007CA2650471A1 Process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate
11/08/2007CA2650422A1 Process for producing polymer micelles encapsulating low molecular weight drugs
11/08/2007CA2650403A1 Compositions comprising theaflavins and gallates thereof useful as fat absorption inhibitors
11/08/2007CA2650393A1 Heterocyclyl-substituted fused pyrazole derivatives and their use
11/08/2007CA2650391A1 Inhibitors of the task-1 and task-3 ion channel
11/08/2007CA2650389A1 Pyrimidine derivatives for the treatment of amyloid-related diseases
11/08/2007CA2650385A1 Novel imidazole derivatives, preparation and user thereof as medicine
11/08/2007CA2650384A1 Novel gem-difluorinated c-glycoside compounds derived from podophyllotoxin, their preparation and their applications
11/08/2007CA2650383A1 Diazeniumdiolated non-steroidal anti-inflammatory drugs, compositions thereof, and related methods
11/08/2007CA2650382A1 Diketo-piperazine and piperidine derivatives as antiviral agents
11/08/2007CA2650376A1 Treatment and screening methods for promoting neurogenesis
11/08/2007CA2650342A1 Chromium complexes
11/08/2007CA2650341A1 Augmentation of titer for vaccination in animals
11/08/2007CA2650326A1 N-(2-thiazolyl)-amide derivatives as gsk-3 inhibitors
11/08/2007CA2650323A1 N-(2-thiazolyl)-amide derivatives as gsk-3 inhibitors
11/08/2007CA2650295A1 Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
11/08/2007CA2650290A1 Pharmaceutical compounds
11/08/2007CA2650119A1 Dihydropyrazolopyrimidinone derivatives
11/08/2007CA2650028A1 Anti-viral agents that activate rnase l
11/08/2007CA2649996A1 Piperidines and related compounds for treatment of alzheimer's disease
11/08/2007CA2649995A1 Amino-ethyl-amino-aryl (aeaa) compounds and their use
11/08/2007CA2649994A1 Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
11/08/2007CA2649993A1 Gem-difluoride c-glycopeptide compounds, their preparation and use particularly for preservation of biological materials.
11/08/2007CA2649861A1 Disubstituted aniline compounds
11/08/2007CA2649822A1 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
11/08/2007CA2649811A1 Triazoloquinazolinone derivatives as inhibitors of checkpoint kinases
11/08/2007CA2649650A1 Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
11/08/2007CA2649601A1 Mono and combination therapy with a m1/m4 muscarinic agonist (sabcomeline) for treatment of cognitive disorders in schizophrenia
11/08/2007CA2649597A1 Mono and combination therapy of m1/m4 agonist (sabcomeline) for treatment of negative symptoms of schizophrenia
1 ... 3512 3513 3514 3515 3516 3517 3518 3519 3520 3521 3522 3523 3524 3525 3526 3527 3528 3529 3530 3531 3532 ... 7860